Japanese Journal of Ophthalmology

, Volume 57, Issue 3, pp 294–300 | Cite as

Choroidal thickness outside the laser irradiation area after photodynamic therapy in polypoidal choroidal vasculopathy

  • Yukinori Sugano
  • Tomohiro Iida
  • Ichiro Maruko
  • Akira Ojima
  • Tetsuju Sekiryu
Clinical Investigation

Abstract

Purpose

To evaluate changes in choroidal thickness adjacent to the area of laser application after photodynamic therapy (PDT) in patients with polypoidal choroidal vasculopathy (PCV) using enhanced depth imaging spectral-domain optical coherence tomography.

Methods

Masked observers measured the choroidal thickness at the subfovea and superior, inferior and temporal areas adjacent to the area of laser application before, 2 days, 1 week and 1 and 3 months after treatment.

Results

Thirty-seven patients with PCV treated with PDT with verteporfin were included. The mean subfoveal choroidal thickness decreased significantly (P < 0.001) from 256 ± 115 μm at baseline to 207 ± 111 μm at 3 months; the mean outside choroidal thickness including the superior, inferior and temporal areas decreased significantly (P < 0.001) from 240 ± 92 μm at baseline to 209 ± 86 μm at 3 months.

Conclusion

PDT affected not only the subfoveal choroid, but also the choroid outside the area of laser application in PCV.

Keywords

Photodynamic therapy Polypoidal choroidal vasculopathy Enhanced depth imaging spectral-domain optical coherence tomography Choroidal thickness 

References

  1. 1.
    Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report 1. Arch Ophthalmol. 1999;117:1329–45.Google Scholar
  2. 2.
    Japanese Age-Related Macular Degeneration Trial (JAT) Study Group. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2003;136:1049–61.CrossRefGoogle Scholar
  3. 3.
    Verteporfin Roundtable 2000 and 2001 Participants; study group principal investigators. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina. 2002;22:6–18.Google Scholar
  4. 4.
    Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina. 2005;25:119–34.CrossRefGoogle Scholar
  5. 5.
    Tano Y, Ophthalmic PDT Study Group. Guidelines for PDT in Japan. Ophthalmology. 2008;115(585):e6.PubMedGoogle Scholar
  6. 6.
    Quaranta M, Mauget-Faÿsse M, Coscas G. Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Am J Ophthalmol. 2002;134:277–80.PubMedCrossRefGoogle Scholar
  7. 7.
    Spaide RF, Donsoff I, Lam DL, Yannuzzi LA, Jampol LM, Slakter J, et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina. 2002;22:529–35.PubMedCrossRefGoogle Scholar
  8. 8.
    Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology. 2004;111:1576–84.PubMedCrossRefGoogle Scholar
  9. 9.
    Otani A, Sasahara M, Yodoi Y, Aikawa H, Tamura H, Tsujikawa A, et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2007;144:7–14.PubMedCrossRefGoogle Scholar
  10. 10.
    Akaza E, Mori R, Yuzawa M. Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina. 2008;28:717–22.PubMedCrossRefGoogle Scholar
  11. 11.
    Saito M, Iida T, Nagayama D. Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment. Br J Ophthalmol. 2008;92:1642–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Yamashiro K, Tsujikawa A, Nishida A, Mandai M, Kurimoto Y. Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy. Jpn J Ophthalmol. 2008;52:457–62.PubMedCrossRefGoogle Scholar
  13. 13.
    Akaza E, Yuzawa M, Mori R. Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2011;55:39–44.PubMedCrossRefGoogle Scholar
  14. 14.
    Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology. 1994;101:1953–61.PubMedGoogle Scholar
  15. 15.
    Kramer M, Miller JW, Michaud N, Moulton RS, Hasan T, Flotte TJ, et al. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy: selective treatment of choroidal neovascularization in monkeys. Ophthalmology. 1996;103:427–38.PubMedGoogle Scholar
  16. 16.
    Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehard U, Viestenz A, Naumann GO. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol. 2002;120:835–44.PubMedGoogle Scholar
  17. 17.
    Schlötzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol. 2002;240:748–57.PubMedCrossRefGoogle Scholar
  18. 18.
    Isola V, Pece A, Parodi MB. Choroidal ischemia after photodynamic therapy with verteporfin for choroidal neovascularization. Am J Ophthalmol. 2006;142:680–3.PubMedCrossRefGoogle Scholar
  19. 19.
    Mukai R, Kishi S, Sato T, Watanabe G, Matsumoto H. Protective effect of intravitreal bevacizumab and sub-tenon triamcinolone acetonide against occlusion of choriocapillaris induced by photodynamic therapy. Ophthalmologica. 2010;224:267–73.PubMedCrossRefGoogle Scholar
  20. 20.
    Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal vascular remodeling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003;87:1453–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Spaide RF, Koizumi H, Pozonni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol. 2008;146:496–500.PubMedCrossRefGoogle Scholar
  22. 22.
    Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T. Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2011;151:594–603.PubMedCrossRefGoogle Scholar
  23. 23.
    Wygnanski-Jaffe T, Desatnik H, Alhalel A, Goldstein M, Lowenstein A, Zolf R, et al. ICG angiography-guided photodynamic therapy for large pigment epithelial detachments in age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2006;37:358–63.PubMedGoogle Scholar
  24. 24.
    Otani A, Sasahara M, Yodoi Y, Aikawa H, Tamura H, Tsujikawa A, et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2007;144:7–14.PubMedCrossRefGoogle Scholar
  25. 25.
    Eandi CM, Ober MD, Freund KB, Slakter JS, Yannuzzi LA. Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization. Retina. 2007;27:825–31.PubMedCrossRefGoogle Scholar
  26. 26.
    Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144:15–22.PubMedCrossRefGoogle Scholar
  27. 27.
    Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol. 2010;94:297–301.PubMedCrossRefGoogle Scholar
  28. 28.
    Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008;92:70–3.PubMedCrossRefGoogle Scholar
  29. 29.
    Hikichi T, Higuchi M, Matsushita T, Kosaka S. Matsushita Ret al. One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Am J Ophthalmol. 2012;154:117–24.PubMedCrossRefGoogle Scholar
  30. 30.
    Sasahara M, Tsujikawa A, Musashi K, Gotoh N, Otani A, Mandai M, et al. Polypoidal choroidal vasculopathy with choroidal vascular hyperpermeability. Am J Ophthalmol. 2006;142:601–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Margolis R, Spaide RF. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol. 2009;147:811–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Maruko I, Iida T, Sugano Y, Ojima A, Sekiryu T. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Retina. 2011;31:1603–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Fujiwara A, Shiragami C, Shirakawa Y, Manabe S, Izumibata S, Shiraga F. Enhanced depth imaging spectral-domain optical coherence tomography of subfoveal choroidal thickness in normal Japanese eyes. Jpn J Ophthalmol. 2012;56:230–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Chung SE, Kang SW, Lee JH, Kim YT. Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology. 2011;118:840–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Koizumi H, Yamagishi T, Yamazaki T, Kawasaki R, Kinoshita S. Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2011;249:1123–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Jirarattanasopa P, Ooto S, Nakata I, Tsujikawa A, Yamashiro K, Oishi A, et al. Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2012;53:3663–72.PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Ophthalmological Society 2013

Authors and Affiliations

  • Yukinori Sugano
    • 1
  • Tomohiro Iida
    • 1
    • 2
  • Ichiro Maruko
    • 1
  • Akira Ojima
    • 1
  • Tetsuju Sekiryu
    • 1
  1. 1.Department of OphthalmologyFukushima Medical University School of MedicineFukushimaJapan
  2. 2.Department of OphthalmologyTokyo Women’s Medical UniversityTokyoJapan

Personalised recommendations